In 2017, only 25% of individuals received one of three Food and Drug Administration approved medications effected at treating opioid use disorder (OUR) from a substance use disorder treatment facility, despite over half of drug overdose deaths involved an opioid. Utilization restrictions may be a significant coverage barrier to accessing these medications as treatment.
This project will determine the association between utilization restrictions when applied to methadone and buprenorphine formulations and a) opioid treatment program DATA-waivered prescribers geographic distribution and b) access to methadone and buprenorphine treatment for opioid dependence.
This project will also answer the following research question: do utilization restrictions primarily affect access to buprenorphine and methadone through their direct impact on the number of opioid treatment programs and DATA-waivered prescribers in an area?
To be released in the Fall of 2020